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International collaboration and
rapid harmonization across
dermatologic COVID-19 registries
To the Editor: Across specialties, coronavirus disease-
2019 (COVID-19) has ushered in an unprecedented
time for international collaboration. As COVID-19
has spread around the world, there has been a
movement among dermatologists to better under-
stand the effects of the virus on their patients as well
as potential dermatologic manifestations of the dis-
ease. During March and April 2020, 8 dermatologic
registries focused on COVID-19 were launched
worldwide to address these issues (Table I).1-3 We
developed a rapid consensus among registry leaders
to foster collaboration and data harmonization.
Members from each international registry came
together in a virtual consensus meeting in April 2020,
facilitated by the American Academy of Dermatology
and the International League of Dermatologic
Societies. Models of collaboration discussed were
(1) linking data across registries for overlapping
conditions at the point of data entry and (2)
harmonizing data post hoc, using shared variables
across registries. As a first step, each dermatologic
registry provided a list of the variables they collect
across several domains, including registry informa-
tion, patient demographics, general medical
information, prior dermatologic conditions, new-
onset skin manifestations in the setting of COVID-
19, and COVID-19erelated history and outcomes
(Supplemental Table I available via Mendeley at
https://data.mendeley.com/datasets/zh6bw88xhc).
This effort formed the basis for a meta-catalog
containing all registry variables so that commonal-
ities and variables in need of harmonization between
studies could be easily identified (Supplemental
Appendix). As a result of this harmonization process,
2 registries have, for example, changed how they
collect demographics to harmonize with other inter-
national registries. Additionally, the registries now
link to each other to facilitate collaboration at the
time of data entry.
Registry leaders also discussed challenges in
collaboration, particularly double data entry across
different registries.4 To address this concern, regis-
tries added a question at the point of data collection
about whether a provider entered a case in another
registry and to identify that registry. This additional
information will enhance our ability to track double
case reporting during analysis, although it is not
possible to fully verify deidentified patient data.
An additional limitation is that registries have, thus
far, originated from North America, Europe, and
Australia. Even though many of these registries are
open to global submissions, most are only available
in English, which may hinder participation. Active
work is needed to include a broader representation
of global dermatologists as well as inclusion of
patients from all racial/ethnic and socioeconomic
groups within each country.5
Ultimately, the reports generated from these
registries will only be as good as the data entered.
As physicians and researchers, we must strive to
include diversity in these reports so that data
collected are representative of the global patient
community we look after. Communication and trans-
parency in data sharing, which may take the form of
regularly posted aggregate data from the registries as
well as periodic update newsletters to dermatology
societies internationally, may be a motivator for the
dermatology community and may encourage
engagement and reporting of cases. Together, we
are most powerful when our collective knowledge is
used to inform the management and care of our
patients affected by COVID-19.
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Table I. General, demographic, and medical information included in coronavirus disease 2019 (COVID-19) dermatology registries
Variable PsoProtect
COVIDSKIN
French registry SECURE Psoriasis SECURE AD
Global HS
COVID-19
Registry SECURE Alopecia
AAD/ILDS Derma-
tology COVID
Registry PeDRA
Date initiated March 27, 2020 March 30, 2020 April 1, 2020 April 1, 2020 April 6, 2020 April 8, 2020 April 8, 2020 April 20, 2020
Website hosted on www.psoprotect.
org
https://bit.ly/
COVIDSKINSFD
covidpso.org covidderm.org https://hscovid.
ucsf.edu
securealopecia.
covidderm.org
www.aad.org/
covidregistry
pedsderm.net;
pedraresearch.
org
Server platform REDCap* sfdermato.org REDCap OpenApp:
Clinical
Insighty
REDCap OpenApp:
Clinical
Insight
REDCap REDCap
Languages
available
English only French only English only English,
Chinese,
Spanish,
French,
Russian
English only English only English only English only
Inclusion criteria
Person entering
data
Health care
professional
or patients
Health care
professional
Health care
professional
Health care
professional
or patients
Health care
professional
or patients
Health care
professional
Health care
professional
Health care
professional
COVID-19
laboratory
confirmed
U U U U U U U U
COVID-19
suspected
U U . U U U U U
Patients on
systemic
medication
included
U U U U U U U U
Patients not on
systemic
medication
included
U U U U U U U U
Patient
demographics
Date of entry
into study
U U U U U U U U
Sex U U U U U U U
Assigned
at birth
U
Assigned
at birth
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Age/year of
birth
U U U U U U U U
Country of
residence
U U U U U U U U
State of
residence
U U
US only
U
US/Australia
U U
US/Australia
U
US only
U
US States/
Canadian
Provinces
Ethnicity U U
US census
categories
U
WHO
categories
U
Originally
US Census;
changed
to WHO
categories
4/26/20
U
WHO categories
U
Originally
US census;
changed
to WHO
4/20/20
U
Currently US
census
categories
General medical
information
Height U U U U
Weight U U U U
Comorbidities
(eg asthma,
COPD, heart
disease, DM)
U U U U U U U U
Smoking status U U U U U U
Alcohol intake U U
NSAIDS U U U U
Existing
dermatologic
condition
Primary
dermatologic
condition
U
Only
psoriasis
U U
Only
psoriasis
U
Only AD
U U
Only
alopecia
U U
Subspecialty
disease
subtype
U U Psoriasis
subtype
U
Alopecia
subtypes
U
Year of
dermatologic
diagnosis
U U U
Name of
dermatologic
medication
U U U
Psoriasis
medications
only
U U U U
Continued
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Table I. Cont’d
Variable PsoProtect
COVIDSKIN
French registry SECURE Psoriasis SECURE AD
Global HS
COVID-19
Registry SECURE Alopecia
AAD/ILDS Derma-
tology COVID
Registry PeDRA
Systemic
medication:
Name U U U U U U U U
Dose and
frequency
U U U U U
Length of
treatment
U U U U
Stopped or
tapered
during
COVID-19
infection
U U U U U
Symptom
activity at time
of COVID-19
diagnosis
U U U U U U
Associated skin
disease flare
with COVID-19
U U U U U U
Skin disease
severity
during COVID-
19 flare
U U U U U
AAD, American Academy of Dermatology; AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; DM, diabetes mellitus; HS, hidradenitis
suppurativa; ILDS, International League of Dermatological Societies; NSAIDS, nonsteroidal anti-inflammatory drugs; PeDRA, Pediatric Dermatology Research Alliance; SECURE, Surveillance
Epidemiology of Coronavirus (COVID 19) Under Research Exclusion; REDCap, Research Electronic Data Capture; US, United States; WHO, World Health Organization.
*Vanderbilt University, Nashville, Tennessee.
yOpenApp, Dublin, Ireland.
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